Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Fengcai Zhu; Pengfei Jin; Tao Zhu; Wenjuan Wang; Huayue Ye; Hongxing Pan; Lihua Hou; Jingxin Li; Xue Wang; Shipo Wu; Ying Wang; Jinbo Gou; Haitao Huang; Hongbin Wu; Xuewen Wang; Wei Chen

Clinical Infectious Diseases (2022) - Comments
doi: 10.1093/cid/ciab845 issn: 1058-4838 issn: 1537-6591 pubmed: 34551104

Fengcai Zhu, Pengfei Jin, Tao Zhu, Wenjuan Wang, Huayue Ye, Hongxing Pan, Lihua Hou, Jingxin Li, Xue Wang, Shipo Wu, Ying Wang, Jinbo Gou, Haitao Huang, Hongbin Wu, Xuewen Wang, Wei Chen

Go to article
Go to preprint

Oxford University Press (OUP)